Aurinia Named Company of the Year by LifeSciences BC

Download as PDF

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) today announced it has received this year’s Company of the Year Award from LifeSciences BC. The 2018 LifeSciences BC award winners will be recognized at this year’s annual dinner presented by FARRIS, held on April 19, 2018 in Vancouver.

“As a company that has its roots in British Columbia, we are thrilled to accept this award,” said Richard M. Glickman, Chairman and CEO of Aurinia. “I am proud of Aurinia’s progress over the last year and our ability to contribute to the advancement of the life sciences in our native British Columbia. Our drive to succeed is fueled by patients and their families, who continue to inspire us as we work to make innovative therapies available as quickly and efficiently as possible.”

About Aurinia
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), minimal change disease MCD and dry eye syndrome (DES). The company is headquartered in Victoria, BC and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.

About LifeSciences BC
LifeSciences BC is a not-for-profit, non-government, industry association that supports and represents the life sciences community of British Columbia through leadership, facilitation of investment and partnering, advocacy, and promotion of our world-class science and industry. Life sciences sectors, from biopharmaceuticals and medical technology, to digital health and medical devices, are integrated into our organization and all that we do, ensuring that no life sciences sector is working in isolation — and that all sectors come together in a comprehensive, complementary and coordinated fashion. Throughout the year, LifeSciences BC undertakes numerous programs and projects in support of these sectors. These include public policy initiatives, facilitating linkages between global industry and our local organizations, raising the profile of our industry internationally and thus facilitating investment and global partnering opportunities, and helping nurture economic development in British Columbia through the life sciences industry.

We seek safe harbor.

Aurinia Pharmaceuticals Inc.
Investor Contact:
Celia Economides
VP, Corporate & Public Affairs
IR@auriniapharma.com
or
Media:
Christopher Hippolyte, 212-364-0458
Christopher.hippolyte@inventivhealth.com

Source: Aurinia Pharmaceuticals Inc.

Released February 20, 2018